Evidence map›Paper›PMID 36849671›Full record

ArticleHead and neck pathology2023

Sinonasal Adenosquamous Carcinoma - Morphology and Genetic Drivers Including Low- and High-Risk Human Papillomavirus mRNA, DEK::AFF2 Fusion, and MAML2 Rearrangement.

Dean Holliday, Mitra Mehrad, Kim A Ely, Fangjia Tong, Xiaowei Wang, Jen-Fan Hang, Ying-Ju Kuo, Jaylou M Velez-Torres, Abberly Lott-Limbach, James S Lewis

Open access · greenAbstract read
In one paragraph

Article in Head and neck pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Case reports in pathology · 2026
    Article
  2. Resistance mechanism to pembrolizumab inInternational cancer conference journal · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Dean HollidayDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Mitra MehradDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kim A ElyDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Fangjia TongDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Xiaowei WangDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Jen-Fan HangDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Ying-Ju KuoDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Jaylou M Velez-TorresDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Abberly Lott-LimbachDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
James S LewisDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. james.lewis@vumc.org.ORCID http://orcid.org/0000-0001-9002-1283
Vanderbilt University Medical Center · USNational Yang Ming Chiao Tung University · TWUniversity of Illinois Chicago · USThe Ohio State University Wexner Medical Center · USUniversity of Miami · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
MICRORNA BIOMARKERS FOR OROPHARYNGEAL CANCERR01DE026471 · NIDCR · WASHINGTON UNIVERSITY · PI WANG, XIAOWEI · 2017 to 2021
$2.2M
Leica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213k
NCI NIH HHS P30 CA068485NIDCR NIH HHS R01 DE026471NIH HHS S10 OD023475NINR NIH HHS S10 OD023475
6 · The paper itself

Abstract

backgroundSinonasal adenosquamous carcinoma is rare, and there are almost no studies detailing morphology or characterizing their genetic driver events. Further, many authors have termed sinonasal tumors with combined squamous carcinoma and glands as mucoepidermoid carcinoma but none have analyzed for the presence of MAML2 rearrangement.

methodsCases from 2014 to 2020 were collected and diagnosed using World Health Organization criteria. They were tested for p16 expression by immunohistochemistry (70% cut-off), DEK::AFF2 fusion by fluorescence in situ hybridization (FISH) and AFF2 immunohistochemistry, MAML2 rearrangement by FISH, and low- and high-risk HPV by RNA ISH and reverse transcription PCR, respectively. Detailed morphology and clinical features were reviewed.

resultsThere were 7 male (64%) and 4 female (36%) patients with a median age of 69 years, most Caucasian (10 of 11 or 91%). Most had tobacco exposure (8/11, 73%) and most presented with epistaxis, a visible nasal mass, and/or facial pain. Several had a precursor papillomas (3 of 11, 27%). The squamous component had variable keratinization, 5 of 11 (46%) of which would be described as keratinizing, 3 non-keratinizing, and 2 with mixed features. All had gland formation, by definition, and 2 of 11 (18%) had ciliated tumor cells. None of the 11 cases had MAML2 rearrangement and one had DEK::AFF2 fusion with associated positive nuclear AFF2 protein immunostaining. Most were p16 positive (7 of 11, 64%) and all 7 of these were hrHPV positive either by RNA ISH or RT-PCR. Two of the p16-negative tumors were positive for lrHPV by RNA ISH. Treatment included surgery alone (4 of 11, 36%), surgery with adjuvant radiation (5 of 11, 45%), and surgery with radiation and chemotherapy (2 of 11, 18%). Four of 11 patients (36%) suffered disease recurrence, two requiring re-operation and who were disease free at last follow-up, one receiving additional chemotherapy and who was alive with disease. The other elected to undergo palliative therapy and died of disease.

conclusionSinonasal adenosquamous carcinoma is a somewhat heterogeneous tumor not infrequently arising ex papilloma and having various drivers including high- and low-risk HPV and rarely DEK::AFF2 fusion. The prognosis appears favorable when proper treatment is possible.

Indexed as

Carcinoma, AdenosquamousCarcinoma, MucoepidermoidPapillomavirus InfectionsParanasal Sinus NeoplasmsAgedFemaleHuman Papillomavirus VirusesHumansIn Situ Hybridization, FluorescenceMaleNuclear ProteinsRNA, MessengerTrans-ActivatorsTranscription FactorsAFF2 protein, humanMAML2 protein, humanNuclear ProteinsRNA, MessengerTrans-ActivatorsTranscription FactorsAdenosquamous CarcinomaDEK::AFF2High-risk HPVLow-risk HPVMAML2Nasal CavityParanasal Sinus

Identifiers

PMID36849671
PMCPMC10293130
OpenAlexW4322488717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.